Relapse · patients with schizophrenia
CLOZAPINE probably leads to lower relapse ‐ short term compared with TYPICAL ANTIPSYCHOTICS ‐ OVERALL (moderate certainty).
4 findings from 1 review
RR 0.62 [0.45, 0.84]
19 studies · 1303 participants
Moderate
RR 0.22 [0.14, 0.34]
4 studies · 578 participants
Moderate
RR 1.04 [0.61, 1.78]
4 studies · 396 participants
Moderate
Show 1 more finding
Global state: no improvement ‐ medium termAs defined in each study · patients with schizophrenia
CLOZAPINE probably leads to lower global impression: 1. Not clinically improved ‐ short term compared with TYPICAL ANTIPSYCHOTICS (moderate certainty).
3 findings from 1 review
RR 0.71 [0.64, 0.79]
4 studies · 370 participants
Moderate
RR 0.83 [0.76, 0.91]
2 studies · 648 participants
Moderate
RR 0.72 [0.66, 0.79]
14 studies · 1119 participants
Moderate
Adverse effects 1. Blood problems · patients with schizophrenia
CLOZAPINE showed no clear difference in adverse effects 1. Blood problems compared with TYPICAL ANTIPSYCHOTICS; GRADE not reported.
1 finding from 1 review
Adverse effects 4. Salivation ‐ too much · patients with schizophrenia
CLOZAPINE probably leads to higher adverse effects 4. Salivation ‐ too much compared with TYPICAL ANTIPSYCHOTICS (moderate certainty).
2 findings from 1 review
Weight gain · patients with schizophrenia
CLOZAPINE probably leads to higher adverse effects 5. Weight gain compared with TYPICAL ANTIPSYCHOTICS (moderate certainty).
2 findings from 1 review
Unable to work · patients with schizophrenia
CLOZAPINE showed no clear difference in unable to work compared with TYPICAL ANTIPSYCHOTICS ‐ OVERALL (moderate certainty).
1 finding from 1 review
Adverse effects: 1. Blood problems ‐ decreased white cell count · patients with schizophrenia
CLOZAPINE probably leads to higher adverse effects: 1. Blood problems ‐ decreased white cell count compared with TYPICAL ANTIPSYCHOTICS ‐ OVERALL (moderate certainty).
1 finding from 1 review
Clinical response: no clinically significant response in mental state: 20% to 50% reduction in PANSS total score · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + RISPERIDONE changes clinical response: no clinically significant response in mental… compared with CLOZAPINE + SULPIRIDE (Kong 2001) (very low certainty).
1 finding from 1 review
Weight gain · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + RISPERIDONE changes adverse effects: weight gain compared with CLOZAPINE + SULPIRIDE (Kong 2001) (very low certainty).
1 finding from 1 review
Clinical response: mean score/change in global state · people with treatment‐resistant schizophrenia
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · people with treatment‐resistant schizophrenia
1 finding from 1 review
Leaving the study early · people with treatment‐resistant schizophrenia
1 finding from 1 review
Service utilisation outcomes: hospital admission or days in hospital · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life/satisfaction with care for either recipients of care or carers: significant change in quality of life/satisfaction · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response: no clinically significant response in mental state · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + RISPERIDONE changes clinical response: no clinically significant response in mental… compared with CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010) (very low certainty).
1 finding from 1 review
Weight gain · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response: mean score/change in global state: mean CGI‐II Global improvement score (high = poor) Short term (6 weeks) · people with treatment‐resistant schizophrenia
1 finding from 1 review
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · people with treatment‐resistant schizophrenia
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + RISPERIDONE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010) (very low certainty).
1 finding from 1 review
Service utilisation outcomes: hospital admission or days in hospital · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found